A potent sedative emerging in Alberta’s unregulated drug market poses a unique challenge for overdose treatment, cautioned a researcher and physician based in Alberta. Medetomidine, a robust non-opioid sedative commonly used in veterinary settings, is increasingly being detected in illicit drug supplies across Alberta, according to Dr. Monty Ghosh, an addiction medicine specialist practicing in Edmonton and Calgary.
Concerns surrounding this sedative came to light in December when reports indicated its growing presence in other provinces, Ghosh mentioned. Since then, a significant surge in medetomidine levels in Alberta’s drug market has been observed, with the sedative being about twice as potent as other tranquilizers previously encountered in the region.
Notably, data from various sources, including wastewater testing in Calgary, drug spot testing, and police drug seizures, have shown a rising prevalence of medetomidine, Ghosh highlighted. In Edmonton, the Spectrum drug testing program, provided by Queer & Trans Health Collective (QTHC), has reported notable increases in medetomidine presence in drug samples.
Kayla Halliday, the harm reduction manager at QTHC, expressed concerns about the implications of medetomidine’s widespread use in drug poisoning emergencies. Unlike fentanyl, medetomidine does not respond to naloxone, making overdose responses more challenging.
While naloxone can address the opioid component of an overdose, there is no direct antidote for medetomidine, Ghosh emphasized. In cases where naloxone fails to reverse the overdose effects, immediate medical assistance should be sought, he advised. Symptoms like a heart rate below 50 beats per minute could indicate medetomidine presence in an overdose situation, Ghosh added.
Despite the presence of medetomidine in Alberta’s illicit drug market, there have been no reported deaths attributed to this substance in the province, a spokesperson from Alberta’s Ministry of Mental Health and Addiction reassured. The spokesperson also highlighted a significant decrease in opioid-related deaths in Alberta since 2023, with most communities returning to pre-pandemic levels, except Edmonton.
Ghosh explained that medetomidine is typically added to drug supplies to prolong the sedative effects of substances, reflecting the dynamic nature of the illicit drug market. The constant evolution of drug combinations underscores the importance of having comprehensive tools, such as Narcan and supervised consumption sites, to address evolving overdose challenges.
While Edmonton Police Service’s drug experts have noted medetomidine’s presence in the city, there has not been a noticeable increase in overdose deaths linked to this sedative, a police spokesperson confirmed.
